Therapy Areas: Oncology
Citius Oncology closes USD9m registered direct offering and concurrent private placement
11 September 2025 - Citius Oncology Inc (Nasdaq:CTOR), the oncology-focused subsidiary of biopharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Wednesday the closing of its ...
Atossa Therapeutics seeks Type C meeting with FDA to accelerate development of low-dose (Z)-endoxifen for breast cancer risk reduction
9 September 2025 - US-based biotechnology company Atossa Therapeutics Inc (Nasdaq:ATOS) announced on Monday that it has requested a Type C meeting with the US Food and Drug Administration (FDA) to dis...
Phanes Therapeutics reports first BTC patient dosed in trial of spevatamig in combination with chemotherapy
9 September 2025 - Phanes Therapeutics Inc, a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced on Monday that the first patient has been dosed...
Oncolytics reports strong efficacy signals for pelareorep in colorectal cancer
8 September 2025 - Immunotherapy company Oncolytics Biotech Inc (NASDAQ: ONCY) on Monday announced positive clinical and translational findings from three metastatic colorectal cancer (mCRC) studies, ...
Anixa Biosciences completes dosing of fourth cohort in ovarian cancer CAR-T trial; Early results show promise
...
Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
8 September 2025 - Johnson & Johnson (NYSE:JNJ), a US-based pharmaceutical and biotechnology company, reported on Saturday that new analyses from the Phase 3 MARIPOSA study shows that first-line t...